208 related articles for article (PubMed ID: 17277926)
1. Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins.
Oberhoff C
Support Care Cancer; 2007 Jun; 15(6):603-611. PubMed ID: 17277926
[TBL] [Abstract][Full Text] [Related]
2. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
Henry DH
Drugs; 2007; 67(2):175-94. PubMed ID: 17284083
[TBL] [Abstract][Full Text] [Related]
3. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P;
Eur J Cancer; 2007 Jan; 43(2):258-70. PubMed ID: 17182241
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
[TBL] [Abstract][Full Text] [Related]
6. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
[TBL] [Abstract][Full Text] [Related]
7. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R
Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
Senecal FM; Yee L; Gabrail N; Charu V; Tomita D; Rossi G; Schwartzberg L
Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
10. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
Herrington JD; Davidson SL; Tomita DK; Green L; Smith RE; Boccia RV
Am J Health Syst Pharm; 2005 Jan; 62(1):54-62. PubMed ID: 15658073
[TBL] [Abstract][Full Text] [Related]
11. Phase III clinical trials with darbepoetin: implications for clinicians.
Glaspy J
Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
[TBL] [Abstract][Full Text] [Related]
13. Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting.
Gascón P
Eur J Cancer; 2005 Nov; 41(17):2601-12. PubMed ID: 16230006
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option.
Cornes P; Coiffier B; Zambrowski JJ
Curr Med Res Opin; 2007 Feb; 23(2):357-68. PubMed ID: 17288690
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
Patton J; Reeves T; Wallace J
Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.
Vansteenkiste J; Rossi G; Foote M
Expert Opin Biol Ther; 2003 Jun; 3(3):501-8. PubMed ID: 12783618
[TBL] [Abstract][Full Text] [Related]
17. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
Hudis CA; Vogel CL; Gralow JR; Williams D;
Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa.
Thames WA; Smith SL; Scheifele AC; Yao B; Giffin SA; Alley JL
Pharmacotherapy; 2004 Mar; 24(3):313-23. PubMed ID: 15040644
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
Morreale A; Plowman B; DeLattre M; Boggie D; Schaefer M
Curr Med Res Opin; 2004 Mar; 20(3):381-95. PubMed ID: 15025847
[TBL] [Abstract][Full Text] [Related]
20. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study.
Gobin J; Cernii A; McLean R; Finkelstein FO; Simon DB
Clin Drug Investig; 2011; 31(2):113-20. PubMed ID: 21067252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
